R&D tie-ups are driver of biomedical growth
Time to diversify the sector by riding on rising Asian middle class and open innovation
[SINGAPORE] FROM pockets of research activity pre-2000, Singapore has built up a global status in the biomedical sciences, with a R&D landscape teeming today with not only all the world's top pharmaceutical and medical technology players but also home-grown capabilities.
And as the biomedical initiative marks another milestone this week - Biopolis, the research hub at one-north, turns 10 - the strategy now is to diversify the sector, riding on two key trends: rise of the Asian middle class and growth of open innovation among companies.
But the focus stays sharply on value creation, says Lim Chuan Poh, chairman of the Agency for Science, Technology and Research (A*Star).
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
New Articles
Singapore top recipient of Q1 cross-border investments in Apac: Knight Frank
Dasin Retail Trust’s trustee-manager chairman, directors deny allegations of misconduct
Keppel Infrastructure Trust posts 29.1% lower Q1 distributable income
Bitcoin faces worst month since FTX crash with ETF demand cooling
AIA launches wealth centre targeting high-net-worth clients
Prudential’s Q1 new business profit down 2% at S$743 million